We are investigating Reata Pharmaceuticals, Inc. (RETA) (“Reata” or the “Company”) for potential violations of the federal securities laws. On August 10, 2020, Reata disclosed in its quarterly report for the second quarter of 2020 that the U.S. Food and Drug Administration (“FDA”) “is not convinced that the MOXIe Part 2 results” of the Company’s study assessing omaveloxolone for the treatment of Friedreich’s ataxia “will support a single study approval without additional evidence that lends persuasiveness to the results. In preliminary comments for the meeting, the FDA stated that we will need to conduct a second pivotal trial that confirms the mFARS results of the MOXIe Part 2 study with a similar magnitude of effect.” On this news, Reata’s stock price fell sharply during intraday trading on August 10, 2020.